Dr. Sriram Venigalla, MD

Dr. Venigalla practices at Penn Medicine Lancaster General Health Physicians Radiation Oncology in Lancaster, Pennsylvania.

Dr. Venigalla's NPI, 1528478724, was assigned on April 28, 2014. Dr. Venigalla graduated from University of Rochester School of Medicine and Dentistry in 2014. Dr. Venigalla holds Pennsylvania license MD459020.

Dr. Venigalla's primary practice is Penn Medicine Lancaster General Health Physicians Radiation Oncology, at 2100 Harrisburg Pike, Lancaster, PA 17601 in Lancaster County. The practice phone is (717) 544-3113.

Dr. Venigalla's primary practice is Penn Medicine Lancaster General Health Physicians Radiation Oncology in Lancaster, Pennsylvania. Dr. Venigalla is also affiliated with Lancaster General Hospital. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Venigalla to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Venigalla practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Venigalla's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Venigalla is licensed in Pennsylvania.

CMS data shows 4,066 Medicare services from Dr. Venigalla across 19 procedure codes in 2024, for 376 Medicare patients. Medicare paid $266,234 for them.

CMS counts 376 Medicare patients who saw Dr. Venigalla in 2024. The largest group is 65 to 74, with 199 patients. 74% of them have cancer, and 73% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Venigalla's median patient age at 72, with 40% women.

In 2024, Dr. Venigalla wrote 309 Medicare Part D claims for 130 patients. 99% of them were for generic drugs. CMS names the drug for 246 of them, across 9 drugs with 11 or more claims each, at $2,168 in total drug cost. In 2023, CMS named 236 claims across 10 drugs.

Dr. Venigalla accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Venigalla as offering telehealth.

Dmand AI links 21 papers to Dr. Venigalla, published from 2011 to 2021. 2018 was the busiest year, with 7. The most frequent topics are Adenocarcinoma, Breast Neoplasms and Prostatic Neoplasms. Dr. Venigalla has published most often in Int J Radiat Oncol Biol Phys. Dr. Venigalla's most frequent co-authors are Jacob Ezra Shabason, MD, David Marshall Guttmann, MD and Varsha Jain, MD.

CMS Open Payments shows 2 general payments to Dr. Venigalla from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Teleflex LLC paid the most, $144.

Dr. Venigalla graduated from University of Rochester School of Medicine and Dentistry in 2014.